Today's key announcements include:
1. **Hogy Medical (Dongyangguang):** The company announced on February 24 that it is planning to acquire control of Yichang Dongshu Yihao Investment Co., Ltd. by issuing shares and raising supporting funds. The transaction is expected to constitute a significant asset reorganization and a connected transaction. It will not result in a change in the company's actual controller. Due to uncertainties, trading of the company's shares was suspended from the market opening on February 24 and will continue from February 25, with an expected total suspension period not exceeding 10 trading days.
2. **Tonde Chemical (Tonde Huagong):** The company announced on February 24 that it and its wholly-owned subsidiaries have received a "Notice of Enforcement" and an "Enforcement Ruling," leading to the freezing and deduction of bank deposits totaling RMB 53.9259 million from the concerned parties.
3. **Palm Eco-Town (Zonglv Gufen):** The company announced on February 24 that it and its subsidiary, Meizhou Zongyuan, have been sued for RMB 113 million due to a construction project contract dispute. The claimed amount represents 6.83% of the company's audited net assets for the most recent fiscal year (2024). The case has been accepted by the court but not yet heard.
4. **Duorei Pharma (Duorui Yiyao):** The company announced on February 24 that a tender offer initiated by Wang Qingtai and Cao Xiaobing, which commenced on January 21, has expired as of February 24. The offer price was RMB 32.07 per share for 19.44 million shares, representing 24.30% of the company's total shares. Trading of the company's shares will be suspended from the market opening on February 25 until the announcement of the tender offer results.
5. **Huazhi Shumei:** The company announced on February 24 that, as of 5:00 PM on February 24, the cumulative box office revenue (including service fees) for the film "Jingzhe Wusheng," in which the company participated as a producer, reached approximately RMB 901 million in mainland China. This exceeds 50% of the company's total operating revenue from its last audited fiscal year. Revenue recognition will begin only after the company recovers its investment costs in the project; as of February 23, the film had no impact on the company's revenue.
6. **Beijing Enlight Media Co.,Ltd. (Guangxian Chuanmei):** The company announced on February 24 that the cumulative box office revenue (including service fees) for the film "Pegasus 3," in which its subsidiary participated, has reached approximately RMB 2.926 billion. This exceeds 50% of the company's total operating revenue from its last audited fiscal year. The company's revenue derived from this film is estimated to be between RMB 43 million and RMB 53 million. Final box office figures are subject to official settlement statements from cinema chains, and copyright sales revenue has not yet been settled.
7. **Jiangsu Xinhua Blue-Sea Film & Video (Xingfu Lanhai):** The company announced on February 24 that its total revenue derived from the two films "Pegasus 3" and "Boonie Bears: The Next Generation," in which it participated as a producer, is estimated to be between RMB 790,000 and RMB 1.02 million. Both films were released in mainland China starting February 17. As of February 23, their seven-day box office revenues were RMB 2.926 billion and RMB 713 million, respectively, each exceeding 50% of the company's revenue from its last audited fiscal year.
8. **Tongwei Co.,Ltd. (Tongwei Gufen):** The company announced on February 24 that it is planning to acquire 100% equity of Qinghai Lihao Qingneng Co., Ltd. by issuing shares and paying cash, and to raise supporting funds. The transaction will not lead to a change in the company's controlling shareholder or actual controller, does not constitute a connected transaction, and is not expected to constitute a significant asset reorganization. Trading of the company's shares, convertible bonds, and conversion rights will be suspended from February 25 for an expected period not exceeding 10 trading days.
9. **Mebon Pharmaceutical (Meibang Gufen):** The company announced on February 24 that its stock price had increased abnormally, with cumulative deviations exceeding 20% over three consecutive trading days. The company stated that its production and operations are normal, with no significant changes in the external environment, and no material undisclosed information. Investors were reminded of risks including the company's P/E ratio being significantly higher than the industry average, potential earnings volatility, and irrational speculation.
10. **China Nuclear Engineering Group (Zhongguo Hejian):** The company announced on February 24 that its shareholder, China Cinda Asset Management, reduced its holding by 8.0354 million shares, or 0.2666% of the total share capital, between November 19, 2025, and February 18, 2026. This reduction plan has now been completed.
11. **Changxin Bochuang:** The company announced on February 24 that it signed a letter of intent to acquire a 93.8108% stake in Shanghai Honghui Guanglian Communication Technology Co., Ltd. for a provisional price of RMB 375 million. The acquisition is part of the company's strategy to expand into the upstream optical communication industry chain.
12. **Beingmate (Bei Yinmei):** The company announced on February 24 that a patent contract dispute, where it is the plaintiff involving RMB 56.8524 million, has been accepted by the court. A counterclaim where it is the defendant, involving RMB 77.2539 million, has also been accepted. Neither case has been heard yet.
**Earnings Previews/Reports:** 1. Ruihua Jishu: 2025 net profit of RMB 107 million, down 7.30% year-on-year. 2. Sansheng Guojian: 2025 net profit of RMB 2.939 billion, up 317.09% year-on-year. 3. Supor: 2025 net profit of RMB 2.097 billion, down 6.58% year-on-year. 4. Wens Foodstuff Group: 2025 net profit of RMB 5.235 billion, down 43.59% year-on-year. 5. Traffic Control Technology: 2025 net profit of RMB 156 million, up 86.13% year-on-year. 6. Sugon: 2025 net profit of RMB 2.113 billion, up 10.54% year-on-year. 7. China Micro Semicon: 2025 net profit of RMB 285 million, up 108.05% year-on-year.
**Share Buybacks & Shareholding Changes:** 1. Yuanli Chemicals: Plans to repurchase shares worth RMB 50-60 million. 2. Jiudian Pharmaceutical: Completed repurchase of 1.24% of shares, totaling RMB 100 million. 3. Shengtian Network: Cumulative repurchase of 3.8409 million shares. 4. Vinda International: Plans to repurchase RMB 60-120 million worth of shares for employee incentives. 5. Anhui Conch Cement: Controlling shareholder plans to increase holding by RMB 700 million - 1.4 billion. 6. Fujian Forecam Optics: Controlling shareholder plans to increase holding by RMB 80-150 million. 7. Xin Zhi Group: Largest shareholder reduced holding by 2.67%. 8. Hengtong Qixiang: Shareholder plans to reduce holding by up to 3%. 9. QianYuan BioPharma: Shareholder has reduced holding by 2.54%.
**Major Contract Awards:** 1. Jiangsu Fengfan: Won a China Southern Power Grid project worth approximately RMB 184 million. 2. China Tianying: Received investment permit expansion for a Hanoi project. 3. *ST Songfa: Subsidiary's contract for building two Capesize bulk carriers recently became effective. 4. Shaoneng Group: Wholly-owned subsidiary signed a land and power plant resource cooperation agreement for an independent energy storage station project. 5. Chengdi Xiangjiang: Subsidiary signed further IDC hosting business agreement with Company X.
**Other Announcements:** 1. Kui Hua Su: Obtained a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolytes Oral Solution. 2. Chengda Biotechnology: Obtained a drug registration certificate for Freeze-dried Human Rabies Vaccine (Human Diploid Cell). 3. Shanghai Pharmaceuticals: Obtained a Singapore drug registration certificate for Rivaroxaban Tablets. 4. Tong Ren Tang: Products including Erganging Oral Solution obtained product registration in Canada.
Comments